Hartree Partners’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Hartree Partners’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,285,000	Closed	-$12.6M	–	102
2022 Q2	$12.6M	Buy	+1,285,000	New	+$12.7M	3%	5
2021 Q4	$12.9M	Hold	1,285,000	–	–	2.99%	7
2021 Q3	$12.8M	Hold	1,285,000	–	–	3.19%	6
2021 Q2	$12.9M	Hold	1,285,000	–	–	3.01%	7
2021 Q1	$12.7M	Buy	+1,285,000	New	+$12.8M	2.19%	9

Other funds holding IBER.U

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Hartree Partners's IBER.U Position: Q3 2022 in Review

Hartree Partners sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q3 2022, closing a stake of 1,285,000 shares — an estimated $12.6M sold.

Hartree Partners first reported a position in IBER.U in Q1 2021 and held it in 5 quarters. The position peaked at $12.9M in Q2 2021. 13 funds tracked by Wall St. Rank hold IBER.U as of Q3 2022.

Hartree Partners reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q3 2022 after selling out during the quarter.
Hartree Partners sold 1,285,000 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q3 2022, an estimated $12.6M.
Hartree Partners first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 5 quarters.
Hartree Partners's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $12.9M in Q2 2021.
13 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q3 2022.

Based on Hartree Partners's 13F filing for Q3 2022, filed 9 Nov 2022.